INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations

Inclusion Criteria: * Age \> 18 years * Diagnosis of prostate cancer as indicated below: Cohort A: patients with high risk localized prostate cancer (defined as \>cT3 or PSA \> 20 ng/mL or presence of ECE or SVIat mpMRI), with tissue available from diagnostic biopsy/ prostatectomy undergoing or who underwent curative treatment (prostatectomy/ radical radiotherapy) but have not started a FU pathway. Cohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC) with tissue available from diagnostic biopsy of the primary and when possiblepossible, from a metastatic site. Patients must either have not started a standard treatment or have started for not longer than 3 months. Cohort C: patients with metastatic castration resistant prostate cancer tissue (mCRPC) progressing on a standard treatment with available from biopsy of a metastatic site, and when possiblepossible, from the primary. * Ability to understand and consent to informed consent; * Patient must be compliant with receiving a biopsy of the metastatic site (cohort C) and with FU assessments schedule Exclusion Criteria: • Patients not willing to comply with study's procedures or fulfilling the inclusion criteria.